lunes, 7 de septiembre de 2020

Russia shares data on vaccine with India, one option is Phase 3 trials here

Senior officials said India had sought this from the Moscow-based Gamaleya Research Institute of Epidemiology and Microbiology. The vaccine candidate triggered a “strong” immune response in Phases 1 & 2 of the clinical trials on 76 people.

Written by Kaunain Sheriff M | New Delhi | Updated: September 7, 2020 10:52:58 am